Daxor’s Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients
Retrieved on:
Wednesday, May 25, 2022
Department, Severe acute respiratory syndrome coronavirus 2, CEO, Risk, Lists of diseases, Private Securities Litigation Reform Act, Observational study, Institute for Music and Neurologic Function, NIH Intramural Research Program, National Institute of Neurological Disorders and Stroke, Leadership, National Institute, Patient, BVA, COVID-19, Mortality, NIH, FDA, Blood volume, Critical care, U.S. Department of Defense Strategy for Operating in Cyberspace, NINDS, Forward-looking statement, Department of Defense Serum Repository, Heart failure, Orthostatic intolerance, National, Exercise intolerance, SEC, GLOBE, Hypertension, Pharmaceutical industry, Stroke
Daxors BVA-100 system is routinely used for numerous medical indications, including critical care, neuro critical care, hypertension, and heart failure.
Key Points:
- Daxors BVA-100 system is routinely used for numerous medical indications, including critical care, neuro critical care, hypertension, and heart failure.
- Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation.
- We developed and market the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.
- Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis.